Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Allogene Therapeutics, Inc. (ALLO) is a Biotechnology company based in US with a market capitalization of $451.2M. Free cash flow was negative at -$149.6M. This page tracks ALLO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 226 employees · IPO Oct 11, 2018
Valuation
Valuation & price
$2.00as of May 17, 2026· -34.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.54
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$451.2M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$149.6M
Free cash flow (USD)
-$175.2M
Net debt
Net cash position
13.3%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2017 → 2025
Free cash flow by year
2017 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 22, 2026Filing
Annual Meeting Results
- 8-K eventMay 28, 2026Filing
CEO Appointment
- 8-K eventMay 13, 2026Filing
Earnings Release
- Quarterly reportMay 13, 2026Filing
10-Q Filed
- Insider sellApr 23, 2026Filing
Insider Sell $22KYoshiyama Annie · SVP, Finance · $22.1K
- 8-K eventApr 15, 2026Filing
Common Stock Offering
- 8-K eventApr 13, 2026Filing
Interim Trial Results
- 8-K eventApr 13, 2026Filing
Public Offering Commenced
- Insider sellApr 2, 2026Filing
Insider Sell $7KBeneski Benjamin Machinas · SVP, Chief Technical Officer · $7.2K
Questions
Frequently asked questions
What is Allogene Therapeutics, Inc.'s market cap?
Allogene Therapeutics, Inc. (ALLO) has a market capitalization of $451.2M.
What is ALLO's P/E ratio?
A meaningful P/E ratio is not available for ALLO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ALLO's price-to-book (P/B) ratio?
ALLO trades at 1.54 times book value per share.
Are insiders buying ALLO stock?
SEC Form 4 filings show no open-market insider buys at Allogene Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.